An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer

[1]  R. Ausman,et al.  Continuous 5-fluorouracil infusion in refractory carcinoma of the breast , 1987, Breast Cancer Research and Treatment.

[2]  Anna L. Brown,et al.  Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  B. Reigner,et al.  Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. Ellis,et al.  Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  H. Gabra,et al.  Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer. , 1996, British Journal of Cancer.

[6]  T. Powles,et al.  Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen. , 1996, British Journal of Cancer.

[7]  T. Powles,et al.  Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  B. Gusterson,et al.  High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  V. Semiglazov,et al.  Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  D. Talbot,et al.  Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  L. Norton,et al.  Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. , 1994, The New England journal of medicine.

[12]  B. Asselain,et al.  Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. , 1994, European journal of cancer.

[13]  V. Bramwell,et al.  A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer. , 1992, European journal of cancer.

[14]  L. Mauriac,et al.  Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  P. Benotti,et al.  Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. , 1990, Annals of internal medicine.

[16]  J. Lokich,et al.  Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. , 1984, Annals of internal medicine.